Kite CAR T-cell Therapy Shows 78% Complete Response, 90% Overall Response Rate in Lymphoma

 - In CIBMTR Registry Analysis, Tecartus Also Demonstrates 88% Complete Response Rate and 94% Overall Response Rate in Second-and-Third-Line Treatment --

-- Data Highlighted in Oral Presentation at ASCO --

 

Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus^® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous hematopoietic cell transplant (autoHCT). Higher CR was seen when Tecartus was given as second-and-third-line compared to later lines of treatment. The data are being presented orally today at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO) (Abstract #7507).

https://www.biospace.com/article/releases/kite-s-tecartus-car-t-cell-therapy-demonstrates-78-percent-complete-response-rate-and-90-percent-overall-response-rate-in-largest-real-world-evidence-analysis-for-relapsed-refractory-mantle-cell-lymphoma/